Extended Data Fig. 4: Antitumour activity of BML-210 and CUDC-101 in mouse breast tumour models with CD4+ or CD8+ T-cell depletion. | Nature Biomedical Engineering

Extended Data Fig. 4: Antitumour activity of BML-210 and CUDC-101 in mouse breast tumour models with CD4+ or CD8+ T-cell depletion.

From: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

Extended Data Fig. 4: Antitumour activity of BML-210 and CUDC-101 in mouse breast tumour models with CD4+ or CD8+ T-cell depletion.

a, Drug-treatment scheme of mouse breast tumour models. b, Flow cytometry gating strategy for analysis of CD4+ and CD8+ T cells from EO771 tumours in C57BL/6 mice. c, Typical graphs showing the proportion of CD4+ and CD8+ T cells in total T cells (CD3+) from EO771 tumours treated with vehicle control or indicated compound, and with CD4 or CD8 depletion. d,e, Proportions of CD8+ (d) and CD4+ (e) T cells in total T cells from EO771 tumours with CD4 or CD8 depletion. f,g, Weight of the EO771 tumours from the tumour-bearing C57BL/6 mice treated with control, CUDC-101 (20 mg kg-1), BML-210 (20 mg kg-1), anti-CD8 (10 mg kg-1) + CUDC-101 (20 mg kg-1), anti-CD8 (10 mg kg-1) + BML-210 (20 mg kg-1), anti-CD4 (10 mg kg-1) + CUDC-101 (20 mg kg-1) or anti-CD4 (10 mg kg-1) + BML-210 (20 mg kg-1). Tumours from tumour-bearing C57BL/6 mice were harvested at day 28 post injection. For statistical analysis of data, two-way ANOVA test was used in (d,e). One-way ANOVA test was used in (f,g). Data are presented as mean ± SD. ****, p < 0.0001; ns, no significance.

Back to article page